Fractyl releases early data on weight recovery after halting obesity drugs; shares plummet

Shares of Fractyl Health GUTS.O fall 62.85% to 62 cents premarket

Co says a small study showed that patients treated with its Revita procedure regained less weight after stopping popular weight-loss drugs than those given a sham treatment

Revita is an experimental endoscopic procedure that modifies a part of the small intestine in patients who had stopped tirzepatide, the active ingredient in Eli Lilly's LLY.N blockbuster weight-loss drug

Co says Revita patients regained 4.5% of their body weight over six months, compared with 7.5% in the sham group

Says top-line six-month data from its larger study and possible U.S. marketing application could come in the second half of this year

GUTS stock rose 6.8% in 2025